{"id":61403,"date":"2026-03-26T15:31:59","date_gmt":"2026-03-26T07:31:59","guid":{"rendered":"https:\/\/flcube.com\/?p=61403"},"modified":"2026-03-26T15:32:00","modified_gmt":"2026-03-26T07:32:00","slug":"ascentage-pharma-2025-revenue-rmb-574m-olverembatinib-nrdl-inclusion-drives-81-growth-lisaftoclax-launches","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61403","title":{"rendered":"Ascentage Pharma 2025 Revenue RMB 574M \u2013 Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches"},"content":{"rendered":"\n

Ascentage Pharma Group International<\/strong> (NASDAQ: AAPG<\/a>, HKG: 6855<\/a>) reported 2025 financial results<\/strong>, with revenue declining 41.5% YoY to RMB 574 million (USD 83.16 million)<\/strong> due to a non-recurring RMB 678 million IP income item in 2024<\/strong>. Excluding this, product sales and commercialization rights revenue surged 90% YoY<\/strong>, driven by olverembatinib (BCR-ABL inhibitor) NRDL inclusion<\/strong> and lisaftoclax (Bcl-2 inhibitor) July 2025 launch<\/strong>. Annual loss widened to RMB 1.243 billion<\/strong>, with RMB 2.47 billion cash<\/strong> supporting continued “dual-engine” oncology execution.<\/p>\n\n\n\n

Financial Highlights<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change<\/th>Adjusted Commentary<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>RMB 574M (USD 83.16M)<\/td>-41.5%<\/td>Excluding 2024 one-time IP income: +90% product\/commercialization growth<\/strong><\/td><\/tr>
Olverembatinib Sales<\/strong><\/td>RMB 435M (USD 63M)<\/td>+81%<\/strong><\/td>NRDL inclusion (January 2025)<\/strong> unlocks volume access<\/td><\/tr>
Lisaftoclax Sales<\/strong><\/td>RMB 70.58M (USD 10.22M)<\/td>Launch revenue<\/td>5-month sales<\/strong> post-July 2025 CLL\/SLL approval<\/td><\/tr>
Net Loss<\/strong><\/td>RMB 1.243B (USD 180M)<\/td>Widened from RMB 406M<\/td>Investment in commercial infrastructure and pipeline<\/td><\/tr>
Cash Position<\/strong><\/td>RMB 2.47B (USD 357M)<\/td>\u2014<\/td>3+ years runway<\/strong> for dual-engine execution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

“Dual-Engine” Commercial Progress<\/h2>\n\n\n\n
Asset<\/th>Mechanism<\/th>2025 Milestone<\/th>Revenue Impact<\/th><\/tr><\/thead>
Olverembatinib<\/strong><\/td>BCR-ABL inhibitor<\/strong> (3rd-gen TKI)<\/td>All approved indications NRDL-included<\/strong> (January 2025)<\/td>81% growth to RMB 435M<\/strong> \u2013 volume acceleration<\/td><\/tr>
Lisaftoclax<\/strong><\/td>Bcl-2 inhibitor<\/strong><\/td>China approval July 2025<\/strong> \u2013 CLL\/SLL post-BTK failure<\/td>RMB 70.58M in 5 months<\/strong> \u2013 rapid uptake in relapsed setting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context: NRDL Transformation<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Olverembatinib Positioning<\/strong><\/td>Only 3rd-gen BCR-ABL TKI<\/strong> in China NRDL; addresses ponatinib-resistant\/intolerant CML<\/strong> patients; ~10,000 addressable CML patients<\/strong> in China<\/td><\/tr>
Lisaftoclax Differentiation<\/strong><\/td>First China-approved Bcl-2 inhibitor<\/strong> post-BTK failure; competes with venetoclax (AbbVie)<\/strong> but oral convenience + CLL-specific label<\/strong> supports market share capture<\/td><\/tr>
Dual-Engine Synergy<\/strong><\/td>Both assets target hematologic malignancies<\/strong> with resistance mechanisms; shared oncology sales force and KOL relationships<\/td><\/tr>
Profitability Pathway<\/strong><\/td>NRDL pricing pressure offset by volume expansion<\/strong>; break-even targeted 2027\u20132028<\/strong> with dual-asset contribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n